Key Highlights

  • SLS shares rose 239.22% pre-market today to $25.34 from a prior close of $7.47.
  • REGAL met its primary endpoint with a hazard ratio of 0.59 (p=0.035).
  • Median overall survival was 24.0 months versus 14.7 months for best available treatment.
  • SELLAS plans a BLA submission in the first half of 2027.

SELLAS Life Sciences (NASDAQ:SLS) shares surged in pre-market today after the company announced positive topline results from the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML). The stock was at $25.34, up 239.22% from the prior close of $7.47, which followed a 4.96% decline in the previous session. The price is above the 52-week high of $15.88.

REGAL met its primary endpoint of overall survival. GPS showed a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a two-sided p-value of 0.035, and median overall survival of 24.0 months versus 14.7 months for investigator's choice of best available treatment. The company called the improvement statistically significant and clinically meaningful.

SELLAS is a New York-based, late-stage clinical biopharmaceutical company developing therapies for a broad range of cancer indications. GPS is a WT1-targeting immunotherapeutic cancer Vaccine licensed from Memorial Sloan Kettering Cancer Center. The company is also developing SLS009 (tambiciclib), a CDK9 inhibitor.

Open-Label Trial Enrolled 126 Patients

The global, randomized, open-label trial enrolled 126 patients, randomized 1:1 to GPS monotherapy or best available treatment, which included observation, a hypomethylating agent, venetoclax or low-dose cytarabine. Patients had achieved a second or later complete remission and were ineligible for, or unable to undergo, allogeneic stem cell transplantation. The analysis followed the pre-specified occurrence of 80 events.

The company said GPS was generally well tolerated, with a safety profile consistent with prior experience and no new safety signals. Treatment-related adverse events were predominantly mild to moderate, most commonly local injection site reactions.

FDA Meeting and BLA Preparations Come Next

SELLAS plans to meet with the FDA to discuss an accelerated filing strategy and is preparing a Biologics License Application for GPS in the first half of 2027. Analysis of secondary endpoints and additional pre-specified analyses is underway, with detailed results to be presented at an upcoming major medical conference and submitted for publication in a peer-reviewed journal. The company hosts a webcast today to discuss the results and next steps.

Regulatory Dialogue and the Full Data Set Frame the Next Phase

The FDA meeting and the detailed secondary endpoint data are the next points to watch. The company noted that final results may differ from the topline data and that the FDA may not agree with its analyses.